The U.S. Food and Drug Administration granted priority review to Nuvalent's lung-cancer therapy, neladalkib, to expedite the drug's evaluation process [1].

This designation accelerates the timeline for a potential market entry, providing a faster path for patients with specific genetic mutations in non-small cell lung cancer to access new treatment options.

Nuvalent filed its New Drug Application for the therapy on April 7, 2026 [4]. The priority review status is intended to speed up the review of drugs that would offer significant improvements in the safety or effectiveness of the treatment of serious conditions [3]. In this case, the therapy targets ROS1- and ALK-positive non-small cell lung cancer [3].

The FDA has set a target action date of Nov. 27, 2026 [2]. This deadline serves as the priority-review date by which the agency aims to complete its assessment of the application [2].

This development marks a rapid expansion for the company. Neladalkib is Nuvalent’s second product to receive priority review in less than one year [1]. The company is positioning itself as a significant player in the oncology space by targeting specific protein kinases that drive tumor growth.

The priority review process does not guarantee approval, but it reduces the time the FDA takes to review the application from the standard 10-month window to six months. By focusing on ROS1 and ALK mutations, Nuvalent is targeting a specific subset of lung cancer patients who may have limited options after previous therapies fail.

“The FDA has set a target action date of Nov. 27, 2026.”

The FDA's priority review indicates that neladalkib addresses an unmet medical need for patients with specific genetic markers in non-small cell lung cancer. For Nuvalent, the rapid succession of priority reviews for two different products suggests a strong pipeline and a strategic focus on precision medicine that could allow the company to capture a specialized market share in oncology.